Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending September 30, 2023

Icosavax Inc Working Capital To Sales Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2023. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue.

Icosavax Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -48.38, a -168.22% change year over year.
Icosavax Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 70.91.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends